Glenmark Launches RYALTRIS Nasal Spray for Allergic Rhinitis in Brazil
Glenmark Pharmaceuticals' subsidiary, Glenmark Specialty S.A., has launched RYALTRIS nasal spray in Brazil following regulatory approval from ANVISA. The spray treats moderate to severe allergic rhinitis symptoms in individuals aged 12 and older. RYALTRIS is the first intranasal combination therapy in Brazil containing olopatadine hydrochloride and mometasone furoate, offering dual-action relief. Allergic rhinitis affects 20-30% of Brazil's population, highlighting the need for effective treatments. The product is Glenmark's first globally commercialized branded innovative therapy, approved in 57 markets worldwide.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 42/100.
Outlets measured: news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 11 Sept, 03:55 am. Other outlets followed.
- 1